BCG is the most effective immunosuppressive agent for intravesical instillation after resection of nonmuscle invasive bladder cancer.
BCG is a live bacterial vaccine made from a suspension of attenuated bovine tubercle bacilli. In addition to being used to prevent tuberculosis, it can also be used for adjuvant treatment of tumors.
Bladder cancer is the most common tumor of the urinary system, and the treatment of bladder cancer is mainly surgical. For non-muscle invasive carcinoma (i.e., the bladder cancer reaches up to the subepithelial connective tissue and does not invade the muscle layer), transurethral resection of bladder tumors with electrolysis (TURBT) is the main treatment. However, there is still a risk of recurrence, or progression to invasive bladder cancer after surgery, so it is important to adjuvant bladder instillation of chemotherapeutic agents after surgery.
BCG is the most effective intravesical instillation immunotherapeutic agent, with superior efficacy to intravesical chemotherapeutic agents, and is usually administered 2 weeks after surgery. BCG reduces the recurrence rate of bladder cancer by 32% relative to mitomycin. Drugs need to be applied under the supervision of a doctor.
Bladder cancer patients are recommended to consult the doctor in time, under the doctor’s guidance for standardized and individualized treatment, regular review, in order to improve the prognosis and prolong the survival period, and at the same time pay attention to the diet and balanced nutrition.